文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma5. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS).

作者信息

Ohmachi Ken

机构信息

Department of Internal Medicine, Division of Hematology and Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara-City, Kanagawa, 259-1143, Japan.

出版信息

Int J Hematol. 2025 May 28. doi: 10.1007/s12185-025-03997-z.

DOI:10.1007/s12185-025-03997-z
PMID:40434571
Abstract
摘要

相似文献

[1]
JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma5. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS).

Int J Hematol. 2025-5-28

[2]
JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-5-diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS).

Int J Hematol. 2019-8

[3]
US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.

J Med Econ. 2023

[4]
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.

Blood. 2022-12-22

[5]
Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model.

BMJ Open. 2025-1-20

[6]
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.

Blood Adv. 2025-5-27

[7]
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan.

J Med Econ. 2023

[8]
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study.

Hematol Oncol. 2025-1

[9]
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2022-1-27

[10]
Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany.

Br J Haematol. 2023-8

本文引用的文献

[1]
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.

Lancet. 2022-6-18

[2]
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2022-1-27

[3]
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.

N Engl J Med. 2022-2-17

[4]
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

N Engl J Med. 2022-2-17

[5]
A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL.

Blood Adv. 2021-11-23

[6]
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

Lancet Oncol. 2021-10

[7]
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.

J Hematol Oncol. 2021-9-8

[8]
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma.

Blood Adv. 2021-10-26

[9]
Maintenance therapy for untreated diffuse large B-cell lymphoma: a systematic review and network meta-analysis.

Ther Adv Hematol. 2021-5-29

[10]
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis.

Crit Rev Oncol Hematol. 2021-7

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索